Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -76.51% is 95% above its 5-year average of -1602.76%, near the high end of its 5-year range (-3758.33%–88.79%).
95.27% above its 12-month average of -1617.38%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3308.51%.
EBITDA MARGIN
-76.51%
EBITDA MARGIN AVG TTM
-1617.38%
EBITDA MARGIN AVG 3Y
-1227.86%
EBITDA MARGIN AVG 5Y
-1602.76%
EBITDA MARGIN AVG 10Y
-5708.99%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+95.27%
CURRENT VS 3Y AVG
+93.77%
CURRENT VS 5Y AVG
+95.23%
CURRENT VS 10Y AVG
+98.66%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SCYNEXIS, Inc.
Market Cap
$30.44M
EBITDA Margin
-76.51%
TTM Avg
-1617.38%
3Y Avg
-1227.86%
5Y Avg
-1602.76%
Market Cap
$30.19M
EBITDA Margin
-3.61%
TTM Avg
-0.43%
3Y Avg
-7.34%
5Y Avg
-19.38%
Market Cap
$30.81M
EBITDA Margin
-5.74%
TTM Avg
-12.14%
3Y Avg
-35.62%
5Y Avg
-63.06%
Market Cap
$30.92M
EBITDA Margin
-10097.04%
TTM Avg
-6618.17%
3Y Avg
-8743.58%
5Y Avg
-8072.84%
Market Cap
$31.11M
EBITDA Margin
-6.58%
TTM Avg
-1.77%
3Y Avg
-0.14%
5Y Avg
1.64%
Market Cap
$29.74M
EBITDA Margin
-17954.61%
TTM Avg
-17954.61%
3Y Avg
-17954.61%
5Y Avg
-17954.61%
Market Cap
$29.37M
EBITDA Margin
-2299.40%
TTM Avg
-2138.43%
3Y Avg
-3018.63%
5Y Avg
-2749.35%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SCYNEXIS, Inc. (SCYX) | $30.44M | -76.51% | -1617.38% | -1227.86% | -1602.76% |
| Rockwell Medical, Inc. (RMTI)vs › | $30.19M | -3.61% | -0.43% | -7.34% | -19.38% |
| MDxHealth S.A. (MDXH)vs › | $30.81M | -5.74% | -12.14% | -35.62% | -63.06% |
| CervoMed Inc. (CRVO)vs › | $30.92M | -10097.04% | -6618.17% | -8743.58% | -8072.84% |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $29.91M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $31.11M | -6.58% | -1.77% | -0.14% | 1.64% |
| GridAI Technologies Corp. (GRDX)vs › | $29.74M | -17954.61% | -17954.61% | -17954.61% | -17954.61% |
| Context Therapeutics Inc. (CNTX)vs › | $29.57M | N/A | N/A | N/A | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.37M | -2299.40% | -2138.43% | -3018.63% | -2749.35% |
| Nortech Systems Incorporated (NSYS)vs › | $31.52M | 2.14% | 1.67% | 3.35% | 2.87% |
Gross Margin
100.0%
EBITDA Margin
-76.5%
Operating Margin
-78.0%
Net Margin
-53.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3308.51% |
| 2025-12-31 | 56.42% |
| 2025-09-30 | -2516.47% |
| 2025-06-30 | -700.95% |
| 2025-03-31 | -3228.79% |
| 2024-12-31 | -776.77% |
| 2024-09-30 | -1496.97% |
| 2024-06-30 | -1197.83% |
| 2024-03-31 | -692.50% |
| 2023-12-31 | -395.65% |
| 2023-09-30 | -565.08% |
| 2023-06-30 | 88.79% |
| 2023-03-31 | -931.95% |
| 2022-12-31 | -1464.96% |
| 2022-09-30 | -1390.56% |
| 2022-06-30 | -1628.12% |
| 2022-03-31 | -2850.51% |
| 2021-12-31 | -3693.63% |
| 2021-09-30 | -3758.33% |
| 2021-03-31 | -12.60% |
| 2019-06-30 | -19531.58% |
| 2019-03-31 | -18412.50% |
| 2018-12-31 | -13681.25% |
| 2018-09-30 | -9820.31% |
| 2018-06-30 | -11964.06% |
| 2018-03-31 | -11300.00% |
| 2017-12-31 | -11187.50% |
| 2017-09-30 | -9996.88% |
| 2017-06-30 | -10479.69% |
| 2017-03-31 | -9398.44% |
| 2016-12-31 | -8775.00% |
| 2016-09-30 | -10471.88% |
| 2016-06-30 | -12912.50% |
| 2016-03-31 | -11264.06% |
| 2015-12-31 | -13107.81% |
| 2015-09-30 | -11776.56% |
| 2015-06-30 | -9951.56% |
| 2015-03-31 | -183.86% |
| 2014-12-31 | -52.03% |
| 2014-09-30 | -79.93% |
| 2014-06-30 | -67.73% |
| 2014-03-31 | -31.31% |
| 2013-12-31 | -59.22% |
| 2013-09-30 | -40.62% |
| 2013-06-30 | -30.10% |
| 2013-03-31 | -15.37% |
